Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.54 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5439934 | 0.96 | SIGMAR1 (0.50) | SIGMAR1PTGDR2OPRM1PDE4APDE4B | |
| SCHEMBL5445050 | 0.83 | HRH3 (0.55) | SIGMAR1PTGDR2HRH3KMT2AKDM4E | |
| SCHEMBL5437516 | 0.82 | TLR8 (0.49) | PTGDR2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL5434732 | 0.81 | TLR8 (0.54) | PDE4B | |
| SCHEMBL31550480 | 0.80 | SIGMAR1 (0.51) | SIGMAR1KDM4EALDH1A1MAPT | |
| SCHEMBL5184776 | 0.80 | RAB9A (0.51) | PTGDR2HRH3POLBMAPT | |
| SCHEMBL5439611 | 0.79 | GSK3A (0.47) | SIGMAR1HRH3KDM4EALDH1A1 | |
| SCHEMBL5442735 | 0.77 | PTGDR2 (0.45) | PTGDR2ALDH1A1 | |
| SCHEMBL5440660 | 0.77 | MAOB (0.41) | PTGDR2HRH3MEN1KMT2AKDM4E | |
| SCHEMBL3175657 | 0.77 | PTGDR2 (0.73) | SIGMAR1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109652-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | ADDEX PHARMACEUTICALS S.A. (CH) | 2013-05-02 | — | — | US | claimed |
| US-20130109652-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | ADDEX PHARMACEUTICALS S.A. (CH) | 2013-05-02 | — | — | US | disclosed |
| US-8399493-B2 | Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20070213323-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | Janssen Pharmaceuticals, Inc. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213323-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | GRM2, GRM1, GRM3 | SIGMAR1 239/4885PTGDR2 85/4885OPRM1 199/4885 |
| US-20130109652-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | GRM2, GRM1, GRIA2 | SIGMAR1 554/4885PTGDR2 78/4885OPRM1 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.